• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Biosimilars: What's in a Name?

Article

BioPharm International speaks to the United States Pharmacopeial Convention to find out who will truly have the final say when it comes to biosimilar nomenclature.

There is still some uncertainty surrounding whether a biosimilar will share the same compendial identity-or biological product monograph-as its reference product. It has been reported that FDA determined that the the United States Pharmacopeial Convention’s (USP’s) monograph for filgrastim does not apply to the first-ever approved biosimilar product, Zarxio (filgrastim-sndz). In this BioPharm International article, Randi Hernandez speaks to USP to find out more about how the naming process for a drug occurs and who truly will have the final say when it comes to biosimilar nomenclature.

http://www.biopharminternational.com/what-s-name-biosimilars-lot

Recent Videos
Ashley Gaines
Related Content
FDA Grants Breakthrough Therapy Designation to Gilead’s Trodelvy for Extensive-Stage Small Cell Lung Cancer

FDA Grants Breakthrough Therapy Designation to Gilead’s Trodelvy for Extensive-Stage Small Cell Lung Cancer

Don Tracy, Associate Editor
December 18th 2024
Article

Breakthrough Therapy designation for Trodelvy was granted based on promising results from the Phase II TROPiCS-03 study, which showed encouraging antitumor activity in both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer.

FDA Approves Celltrion’s Stelara Biosimilar for Multiple Indications

FDA Approves Celltrion’s Stelara Biosimilar for Multiple Indications

Don Tracy, Associate Editor
December 18th 2024
Article

Approval of Steqeyma was based on a comprehensive evidence review, including a Phase III trial in moderate to severe plaque psoriasis.

Merck, Johnson & Johnson Submit Biologics License Applications for Pediatric Respiratory Syncytial Virus, Ulcerative Colitis

Merck, Johnson & Johnson Submit Biologics License Applications for Pediatric Respiratory Syncytial Virus, Ulcerative Colitis

Don Tracy, Associate Editor
December 18th 2024
Article

New biologics license applications seek FDA approval for Merck’s clesrovimab to protect infants and children from respiratory syncytial virus and Johnson & Johnson’s Simponi for the treatment of ulcerative colitis.

FDA Approves Organon’s Vtama Cream, 1% for Atopic Dermatitis

FDA Approves Organon’s Vtama Cream, 1% for Atopic Dermatitis

Don Tracy, Associate Editor
December 17th 2024
Article

Approval of Vtama for atopic dermatitis provides a steroid-free treatment option for adults and pediatric patients.

FDA Grants Breakthrough Therapy Designation to GSK’s Jemperli for Locally Advanced Mismatch Repair Deficient/Microsatellite Instability-High Rectal Cancer

FDA Grants Breakthrough Therapy Designation to GSK’s Jemperli for Locally Advanced Mismatch Repair Deficient/Microsatellite Instability-High Rectal Cancer

Don Tracy, Associate Editor
December 16th 2024
Article

The Breakthrough Therapy Designation for Jemperli was based on Phase II clinical trial data, showing a 100% clinical complete response rate in patients with locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.

A Rocky Road for Regulation

A Rocky Road for Regulation

Mike Hollan
December 16th 2024
Article

With the Inflation Reduction Act now in flux, how will the government and industry respond?